Health Care & Life Sciences » Pharmaceuticals | Zhejiang Starry Pharmaceutical Co. Ltd.

Zhejiang Starry Pharmaceutical Co. Ltd. A | Income Statement

Fiscal year is January-December. All values CNY Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
682,039.50
654,664.10
695,180.90
665,939.90
700,865.30
877,962.20
Cost of Goods Sold (COGS) incl. D&A
515,167.50
465,427.40
451,523.40
428,059.50
458,762.50
562,767.40
Gross Income
166,872.00
189,236.60
243,657.60
237,880.50
242,102.90
315,194.80
SG&A Expense
67,237.00
76,817.60
104,248.60
118,445.90
122,231.70
140,674.60
EBIT
97,473.50
107,823.40
130,144.40
122,857.30
119,463.00
172,952.60
Unusual Expense
-
-
-
1,383.30
-
-
Non Operating Income/Expense
206.70
521.20
5,773.30
142.90
16,067.20
4,650.40
Interest Expense
28,798.30
33,481.60
38,223.30
26,242.70
36,015.80
66,303.90
Pretax Income
73,806.00
79,848.30
93,371.90
97,041.50
101,915.50
117,031.90
Income Tax
11,006.40
12,822.30
19,905.30
21,543.00
22,067.40
23,178.20
Equity in Affiliates
-
-
-
407.00
1,576.80
1,685.40
Consolidated Net Income
62,799.70
67,026.00
73,466.50
75,905.60
81,425.00
95,539.20
Net Income
63,657.70
67,704.20
68,944.10
76,121.50
83,117.00
93,676.40
Net Income After Extraordinaries
63,657.70
67,704.20
68,944.10
76,121.50
83,117.00
93,676.40
Net Income Available to Common
63,657.70
67,704.20
68,944.10
76,121.50
83,117.00
93,676.40
EPS (Basic)
0.53
0.56
0.57
0.63
0.69
0.56
Basic Shares Outstanding
120,000.00
120,000.00
120,000.00
120,000.00
120,000.00
168,000
EPS (Diluted)
0.53
0.56
0.57
0.63
0.69
0.56
Diluted Shares Outstanding
120,000.00
120,000.00
120,000.00
120,000.00
120,000.00
168,000
EBITDA
141,898.30
159,534.80
188,904.40
187,619.90
193,521.80
260,273.40
Other Operating Expense
2,161.60
4,595.60
9,264.60
3,422.70
408.20
1,567.60
Non-Operating Interest Income
599.50
712.00
423.30
1,667.30
2,401.10
3,798.90
Minority Interest Expense
858.10
678.20
4,522.40
216.00
1,692.00
1,862.80

About Zhejiang Starry Pharmaceutical Co.

View Profile
Address
9 Fengxi West Road
Taizhou Zhejiang 317306
China
Employees -
Website http://www.starrypharm.com
Updated 07/08/2019
Zhejiang Starry Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of active ingredient and intermediate X-CT non-ionic contrast agent and fluoroquinolones series. Its products include fluorine quinoline derivatives, carbapenem, iohexol, ioversol, iopamidol, iopromide, iodixanol, levofloxacin, levofloxacin hydrochloride, levofloxacin acid ester, levofloxacin acid, pazufloxacin, pazufloxacin mesylate, meropenem, faropenem sodium, iomeprol, and gadobenate dimeglumine. The company was founded on September 15, 1997 and is headquartered in Taizhou, China.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.